company background image

Evolus NasdaqGM:EOLS Stock Report

Last Price


Market Cap







05 Oct, 2022


Company Financials +
EOLS fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance0/6
Financial Health4/6

EOLS Stock Overview

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.

Evolus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Evolus
Historical stock prices
Current Share PriceUS$8.85
52 Week HighUS$14.34
52 Week LowUS$5.06
1 Month Change-2.32%
3 Month Change-31.66%
1 Year Change24.65%
3 Year Change-37.50%
5 Year Changen/a
Change since IPO-23.04%

Recent News & Updates

Sep 21

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus (NASDAQ:EOLS) said Wednesday it concluded certain royalty payments related to the 2021 settlement of litigation claims between the company, Medytox and Allergan - which is now part of AbbVie (ABBV). EOLS continues to expect its adj. gross profit margin for the quarter ending Dec. 31 to grow 68-71%. "The conclusion of these royalty payments represents the beginning of a significantly improved financial profile reflecting stronger profit margins, which keeps us on a path to reaching profitability," said EOLS CEO David Moatazedi.

Sep 11

Evolus: Turning That Frown Upside Down

Summary Today, we circle back on Evolus Inc. for the first time in 2022. The company is delivering impressive revenue growth and marching towards profitability in FY2024. The company continues to take market share in the aesthetic neurotoxin space. An investment analysis follows in the paragraphs below.

Aug 30

Evolus appoints Experian's exec as CFO

Evolus (NASDAQ:EOLS) on Tuesday has named Sandra Beaver as its chief financial officer, effective Sept. 5, 2022.  Most recently, Beaver served as Senior Vice President of Finance at Experian (OTCQX:EXPGF) and previously has worked for 17 years with global gaming company International Game Technology (IGT). Beaver roles at IGT included Vice President of Consolidated Financial Planning & Analysis and Vice President and CFO of the company’s North America Gaming and Interactive business unit. "As our new CFO, she will play a pivotal role in supporting our strategic goals as we continue to gain market share in the U.S. with our flagship product, Jeuveau, expand operations in Europe and internationally, and execute on our mission to become a global, multi-product organization," commented David Moatazedi, President and CEO at Evolus.  Earlier: Evolus down 13% on 2022 guidance below estimates, wider-than-expected Q2 loss

Shareholder Returns

EOLSUS PharmaceuticalsUS Market

Return vs Industry: EOLS exceeded the US Pharmaceuticals industry which returned 5.8% over the past year.

Return vs Market: EOLS exceeded the US Market which returned -18.2% over the past year.

Price Volatility

Is EOLS's price volatile compared to industry and market?
EOLS volatility
EOLS Average Weekly Movement10.4%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement7.0%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: EOLS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: EOLS's weekly volatility (10%) has been stable over the past year.

About the Company

2012174David Moatazedi

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc. Fundamentals Summary

How do Evolus's earnings and revenue compare to its market cap?
EOLS fundamental statistics
Market CapUS$496.44m
Earnings (TTM)-US$78.58m
Revenue (TTM)US$132.41m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EOLS income statement (TTM)
Cost of RevenueUS$56.35m
Gross ProfitUS$76.05m
Other ExpensesUS$154.64m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 30, 2022

Earnings per share (EPS)-1.40
Gross Margin57.44%
Net Profit Margin-59.35%
Debt/Equity Ratio152.7%

How did EOLS perform over the long term?

See historical performance and comparison